An EpiPen For Heart Attacks? Idorsia Launches Phase III Study Of Selatogrel

Rapid-Onset Anti-Platelet Drug Shows Promise

 
• By Andrew McConaghie

Jean-Paul Clozel, whose firm Actelion was bought by Johnson & Johnson for $30bn, is back with his new company and a new approach to help save the lives of heart attack patients.

Idorsia building
Idorsia is anticipating US FDA approval of its first candidate, insomnia drug daridorexant in 2022, with selatogrel among several late-stage assets. • Source: Idorsia

More from Clinical Trials

More from R&D